Tag - CRDL

Feature

Cardiol Therapeutics Advancing Life-Changing Therapies for Heart Disease, Showing Potential to Reverse Inflammation-Driven Structural Damage

Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) is emerging as a leader in the development of anti-inflammatory and anti-fibrotic medicines designed to counteract the fundamental biological processes that drive...

December 2, 2025

Markets

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform” from “outperform” and trimmed its price target to $4 (Canadian) from $5, citing a slower than expected enrollment in Cardiol’s LANCER clinical...

March 16, 2022

Markets

Cantor starts Cardiol at OW; PT $8

Cantor Fitzgerald launched coverage of Cardiol Therapeutics (NASDAQ:CRDL) with an “overweight” rating and price target of $8. The stock closed at $1.87 on Dec. 16. Cardiol is a clinical-stage, platform-enabled...

December 17, 2021

Markets

Raymond James ups Cardiol Therapeutics to OP from MP

Raymond James upgraded Cardiol Therapeutics (TSX:CRDL) to “outperform” from “market perform,” citing enrollment of the first patient in a Phase 2/3 clinical trial investigating the cardioprotective properties of...

April 28, 2021

Markets

Leede Jones Gable starts Cardiol Therapeutics at speculative buy; PT $12.50 (Canadian)

Leede Jones Gable initiated coverage of Cardiol Therapeutics (TSX:CRDL) with a “speculative buy” rating and price target of $12.50 (Canadian). The stock closed at $4.51 on March 24. Analyst Doug Loe, Ph.D., writes that...

March 25, 2021

Tag - CRDL

Cardiol Therapeutics Advancing Life-Changing Therapies for Heart Disease, Showing Potential to Reverse Inflammation-Driven Structural Damage

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Cantor starts Cardiol at OW; PT $8

Raymond James ups Cardiol Therapeutics to OP from MP

Leede Jones Gable starts Cardiol Therapeutics at speculative buy; PT $12.50 (Canadian)

Subscribe